Skip to content

Preclinical drug screening and evaluation

Scientists at the ICT have considerable expertise in preclinical pharmacology, especially in the cancer field. We have performed collaborative research with numerous companies over many years and have an excellent reputation for delivering high quality research for our commercial partners:

Our key areas of expertise include:

  • Target identification and characterisation
  • Cellular Cytotoxicity
  • Cellular growth inhibition evaluation
  • Evaluation of tumour dissemination processes
  • Tumour xenograft models
  • Hollow fibre assay
  • Site specific tumours
  • Cell lines & xenografts

For further information regarding the ICTs preclinical pharmacology services please contact Dr. Steve Shnyder

ICT Lab image

Areas of investigation

Target Identification and Characterisation

  • Immunohistochemistry
  • Tissue and tumour arrays
  • Gene expression
  • Tumour/normal differential expression evaluation
  • Development of genetically modified experimental models
  • Drug-target interaction evaluation
  • Analysis of molecular pharmacology of drug action

Cellular Cytotoxicity

  • MTT/SRB microplate cytotoxicity assays
  • Clonogenic assay
  • Tumour versus normal cell response
  • Drug response in three-dimensional tumour sphere

Cellular Growth Inhibition Evaluation

  • Cell cycle analysis
  • Apoptosis/cell death induction
  • Mechanistic studies

Evaluation of tumour dissemination processes

  • Cell adhesion assay
  • Cell migration assay
  • Cell invasion assay
  • Cell angiogenesis assay
  • Both 2D and 3D models